Protection against Delta variant

A pre-clinical trial of opaganib from Israel’s Redhill (see here previously) shows that its strong antiviral and anti-inflammatory activities can inhibit any variant of the SARS-Cov-2 virus. Opaganib targets SK2 – a key enzyme used by the virus to replicate, irrespective of spike protein mutations.

https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=4457&PID=0&IID=21354

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.